Fresh2 Group Limited (FRES)
Fresh2 Group Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $0.85, down 23.42% on the session, giving a market capitalisation of $2.1M. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -846.0%. Its beta of 1.28 implies it has historically moved more than the broad market.
Fresh2 Group Limited, a biotechnology company established in New York, New York, in 2010, officially adopted its current name in April 2023, having previously been known as AnPac Bio-Medical Science Co., Ltd. The company is primarily engaged in the research, development, promotion, and sale of advanced multi-cancer screening and detection tests within the People's Republic of China, leveraging its proprietary cancer differentiation analysis (CDA) technology and associated devices for corporate and life insurance clients. Beyond these core diagnostic offerings, Fresh2 Group provides comprehensive physical checkup packages and an array of technology services, including market research, design, software coding, development, and testing. The company also markets genetic testing kits and various skincare products. It owns several fundamental technology platforms and actively participates in further technological innovation and product distribution. Adding a unique dimension to its operations, Fresh2 Group also manages an e-commerce platform that facilitates connections between food suppliers and both supermarket operators and restaurant owners.
Fresh2 Group Limited is most often compared with the following Healthcare names: